AbbVie Inc. (ABBV)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
What's better than receiving passive income? Enjoying it for decades.
Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
My Best Dividend Aristocrats For December 2024
The ProShares S&P 500 Dividend Aristocrat ETF is up 10.26% year-to-date through October. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 40 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the rally.
Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead
AbbVie's stock dropped 17.3% due to Emraclidine's phase 2 trial failure, but management is expected to replace Humira revenues and grow the top line. Skyrizi and Rinvoq are projected to surpass Humira's peak revenues by 2027, indicating strong future growth in the immunology segment. Oncology and neuroscience segments show promise with acquisitions like ImmunoGen and Aliada, despite setbacks in schizophrenia drug development.
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
Key Points Donald Trump's victory is positive for the stock market.
Dividend Aristocrats Yielding Over 4% to Buy in November
Companies with high dividend yields are relatively uncommon in this market.
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock in the index is trading at more than 25 times earnings.
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
AbbVie: Upgrading To 'Strong Buy' After Pullback
In recent days, financial market participants have remained pessimistic about AbbVie's prospects, mainly due to the data on clinical outcomes related to emraclidine. However, I believe Mr. Market overreacted to this news, given the increase in dividend payments and the full-year non-GAAP EPS. AbbVie continues to be a leader in the global immunology market, thanks in part to the strong performance of its two stars, Skyrizi and Rinvoq.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
